Tag:
vemurafenib
Latest Headlines
Latest Headlines
Report: Senate staffers hammering out accelerated drug approval pathway
BIO and Sen. Kay Hagan (D-NC) are working on draft legislation that would clear a shortcut through clinical trials straight through to the FDA for developers engaged in rare disease drug work,
Roche wins early approval for blockbuster melanoma drug vemurafenib
In a rare move, the FDA has stamped an early approval on Roche's remarkable new melanoma drug, vemurafenib, giving it a green light on a potential new blockbuster two months ahead of its PDUFA date.
Report: FDA approval for Roche's melanoma drug vemurafenib 'imminent'
Quoting sources, Reuters reports that Roche's remarkable experimental melanoma drug vemurafenib appears headed for an early approval by the FDA. Roche filed for an approval in May, putting it in line
Roche's vemurafenib plays a starring role at ASCO
Vemurafenib , the experimental melanoma drug advanced by Plexxikon and now spearheaded by Roche, emerged as the clear star of ASCO over the weekend. Cancer experts were cheered by the news that 84
Globe highlights targeted cancer drugs from Pfizer, Roche ahead of ASCO
The Boston Globe this morning noted Pfizer's crizotinib and Roche's vemurafenib as two poster children of sorts for drugs developed to target the molecular drivers of cancer growth. And the targeted
BMS, Roche join forces and drugs on combo melanoma program
If you want to attack an aggressive killer like metastatic melanoma, it's best to target it from as many angles as possible. That's the approach that Roche is taking with its promising late-stage
Roche, GSK melanoma drugs in ASCO's "hottest" spotlight
With Roche eager to discuss at ASCO how its closely-watched melanoma drug vemurafenib --in-licensed from Plexxikon--extended the survival of patients in a key study, Bloomberg takes an in-depth look
Roche cancer programs angle for a starring role at ASCO
Roche set the stage for its upcoming review of new mid- and late-stage data on vemurafenib--its closely watched experimental treatment for skin cancer licensed in from Plexxikon-at the annual ASCO
